Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zimberelimab - Arcus Biosciences/Guangzhou Gloria Biosciences/Taiho Pharmaceutical

Drug Profile

Zimberelimab - Arcus Biosciences/Guangzhou Gloria Biosciences/Taiho Pharmaceutical

Alternative Names: AB 122; GLS 010; GS-0122; WBP 3055; YUTUO

Latest Information Update: 15 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator WuXi Biologics
  • Developer Arcus Biosciences; Gilead Sciences; Guangzhou Gloria Biosciences; Memorial Sloan-Kettering Cancer Center; Strata Oncology; Taiho Pharmaceutical; UCLAs Jonsson Comprehensive Cancer Center; University of Texas Southwestern Medical Center; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer; Hodgkin's disease
  • Phase III Gastrointestinal cancer; Non-small cell lung cancer
  • Phase II Biliary cancer; Liposarcoma; Liver cancer; Malignant melanoma; Rectal cancer
  • Phase I/II Colorectal cancer; Pancreatic cancer; Solid tumours
  • Phase I Cancer; Glioblastoma
  • Discontinued Prostate cancer

Most Recent Events

  • 01 Feb 2024 Arcus Biosciences terminates a phase-I/II trial in Adenocarcinoma (Combination therapy, Late-stage disease, Inoperable/Unresectable, First-line therapy) and Pancreatic cancer (Combination therapy, First-line therapy, Late-stage disease) in USA (IV) due to early accrual (NCT05688215)
  • 27 Oct 2023 Arcus Biosciences in collaboration with Vanderbilt-Ingram Cancer Center withdraws a phase Ib PANTHEoN trial in Head and neck cancer (Late-stage disease, Combination therapy) (PO), prior to enrolment due to funding (NCT04892875)
  • 06 Oct 2023 Arcus Biosciences completes enrolment in the phase I/II ARC-9 trial for Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, France, Italy, South Korea, Spain and UK (PO) (NCT04660812)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top